D evelopment of the embryonic vasculature depends on vasculogenesis (de novo formation of blood vessels) and angiogenesis (branching of preexisting blood vessels) in a process requiring appropriate levels of vascular endothelial growth factor (VEGF). Targeted disruption of the Vegf gene produces an embryonic lethal phenotype displaying impaired blood island formation and delayed endothelial cell differentiation, leading to abnormal blood vessel development.
1,2 VEGF is the ligand for tyrosine kinase receptors Flk1 and Flt1, both of which are expressed in endothelial cells and their mesenchymal precursors. Flk1 −/− mice die in utero because of inhibition of vasculogenesis and formation of angioblast cells in the blood islands, 3 whereas Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) is a congenital disorder of neonates and infants, which is characterized by severe defects in development of pulmonary capillaries, hypoxemia, pulmonary hypertension and thickening of small pulmonary arteries, malposition of pulmonary veins, lung edema, and impaired lobular development. 8 Structural abnormalities of the genitourinary, gastrointestinal, and cardiovascular systems are also common. Because of the severity of developmental defects and progressive respiratory insufficiency in ACD/MPV infants, the survival after the first month of birth is rare. 8 Although genetic factors associated with ACD/MPV are not fully characterized, heterozygous deletions and point mutations in the Forkhead Box transcription factor F1 (FOXF1) gene locus account for ≈40% of ACD/MPV cases. 9 In addition, genomic deletions in FOXF1 gene were recently found in prenatal cystic hygroma, 10 a congenital vascular defect that can result in fetal hydrops (tissue edema) and embryonic death. These clinical data illustrate a critical role of FOXF1 in vascular development.
FOXF1 protein (previously known as HFH-8 or Freac-1) is a member of the Forkhead Box (Fox) family of transcription factors that share homology in the Winged helix/Forkhead DNA-binding domain. FOXF1 is expressed in extraembryonic mesoderm, allantois, splanchnic mesoderm, and septum transversum mesenchyme. 11, 12 Foxf1 −/− mice die by E8.5 because of severe abnormalities in development of the yolk sac and allantois. 13 Although FOXF1 haploinsufficiency causes alveolar capillary dysplasia, fusion of the lung lobes and various developmental defects in mesenchyme of the gallbladder, esophagus, and trachea, 12, 14, 15 Foxf1 +/− mice do not recapitulate all histopathologic features of human ACD/MPV. Approximately half of Foxf1 +/− mice survived past birth, 14 but these mice exhibited severe pulmonary hemorrhage in response to lung injury 16 and abnormal liver regeneration after liver injury. 17 FOXF1 is activated by the Shh signaling pathway through a direct binding of Gli transcription factors to the Foxf1 promoter region. 15, 18 Deletions of Gli-binding sites were found in the FOXF1 gene locus of ACD/MPV patients. 19 Shh −/− mouse embryos exhibit a reduction in Foxf1 mRNA, 15 implicating Shh/ Gli signaling in regulation of Foxf1 gene expression. FOXF1 induces migration of mesenchymal cells through direct transcriptional activation of Integrin β3 and Notch-2 genes. 20, 21 Although FOXF1 is expressed in multiple mesenchyme-derived cell types, including fibroblasts, peribronchial smooth muscle, endothelial, and hepatic stellate cells, cellular origins and molecular mechanisms of developmental abnormalities in FOXF1-deficient mice and ACD/MPV patients remain uncharacterized because of the lack of mouse models with cell-restricted inactivation of the Foxf1 gene. In the present study, we generated mice harboring Foxf1-floxed alleles and used Tie2-Cre and Pdgfb-CreER transgenes to investigate the role of FOXF1 in endothelial cells. We demonstrated that FOXF1 is critical for formation of embryonic vasculature by stimulating endothelial proliferation and promoting the VEGF, PDGF, and Angpt/Tie2 signaling pathways in endothelial cells through direct transcriptional activation of Flk1, Flt1, Pdgfb, and Tie2 genes.
Methods

Generation of Foxf1-Floxed Mice and Deletion of FOXF1 From Endothelial Cells
Foxf1-targeting vector contained a LoxP site inserted into the Foxf1 promoter and PGK-gb2 LoxP/FRT-flanked Neomycin (neo) cassette placed into the first intron ( Figure 2A ). The PGK promoter-driven herpes simplex virus-thymidine kinase gene was placed outside of the Foxf1 gene homology region for negative selection of nonhomologous recombination in embryonic stem (ES) cells. The Foxf1 fl -targeting vector was used for electroporation of mouse ES cells (C57Bl/6x129/SVEV), which were selected for neo (G418) and herpes simplex virus-thymidine kinase resistance (ganciclovir). ES cells with the appropriate Table I ). To produce Foxf1 fl/+ mice, chimeric mice were bred with C57Bl/6 mice in the animal facility of Cincinnati Children's Hospital Medical Center. The Neo cassette was deleted by breeding of Foxf1 fl/+ mice with ACT-FLP1 mice (Jackson Laboratory; Figure 2A ). The loss of Neo in Foxf1 fl/+ mice was confirmed by PCR using P5 and P6 primers (Figure 2A ; Online Table I ).
Foxf1
fl/+ mice were backcrossed to generate viable Foxf1 fl/fl mice that were bred into the C57Bl/6 background for 10 generations. Deletion of the Foxf1 fl alleles from endothelial cell lineage was accomplished through breeding with Tie2-Cre (C57Bl/6; Jackson Laboratory) and Pdgfb-CreER (C57Bl/6 22 ) transgenic mice. To activate Pdgfb-CreER, tamoxifen was given in food (200 mg of tamoxifen citrate with 24.8 g sucrose per kilogram of diet; Harlan Laboratory) at E9.5. For postnatal activation of Cre, tamoxifen was injected intraperitoneally (20 μg per day) at postnatal days P0, P1, and P2. Deletion of FOXF1 was confirmed by breeding FOXF1-deficient mice with LoxP-stop-LoxP-β-gal (R26R) and LoxP-tdTomato-LoxP-GFP (mT/mG) reporter mice (both from Jackson Laboratory). Flk1-null mutant mice were previously described. 23 Animal studies were approved by the Animal Care and Use Committee of Cincinnati Children's Hospital Research Foundation.
RNA Preparation and Quantitative Real-Time Reverse Transcriptase PCR
Total RNA was prepared from MFLM-91U cells, mouse tissue, and flow-sorted endothelial cells using RNeasy micro kit (Qiagen). Quantitative reverse transcriptase PCR analysis was performed using a StepOnePlus Real-Time PCR system (Applied Biosystems) as described. 24 Samples were amplified using inventoried TaqMan primers (Online Table II ). Reactions were analyzed in triplicates, and expression levels were normalized to β-actin mRNA.
Small Interfering RNA Transfection, Western Blot, and Matrigel Angiogenesis Assay
MFLM-91U cells 20 were cultured in serum-free UltraCULTURE medium (Lonza, Walkersville, MD). To inhibit FOXF1, we transfected either nontargeting small interfering RNA or small interfering RNA specific to mouse Foxf1 (Dharmacon) using Lipofectamine 2000 reagent (Invitrogen) as described. 20 
Immunohistochemical Staining and Flow Cytometry
Paraffin sections were stained with H&E or used for immunohistochemical staining as described. 26, 27 Primary antibodies and detection systems are listed in the Online Data Supplement. For colocalization experiments, secondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen) were used as previously described. 28, 29 Slides were counterstained with DAPI (Vector Laboratory). Fluorescent images were obtained using a Zeiss Axioplan2 microscope equipped with an AxioCam MRm digital camera and AxioVision 4.3 Software (Carl Zeiss Microimaging, Thornwood, NY). Flow cytometry was performed using cells isolated from yolk sacs and lungs as described. 27, 30 Antibodies used for flow cytometry are listed in the Online Data Supplement. BrdU was injected intraperitoneally into pregnant females 2 hours before embryo harvest. Annexin V kit was from eBioscience. Stained cells were separated using cell sorting (Five-laser FACSAria II; BD Biosciences). Purified cells were used for RNA preparation and quantitative reverse transcriptase PCR analysis.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assay was performed using in situ cross-linked MFLM-91U cells as described. 24, 27 Antibodies used for ChIP were: FOXF1 20 and control rabbit IgG (Vector Laboratory). Sense and antisense PCR primers that were used to amplify mouse promoter DNA fragments in ChIP assay are provided in Online Table III .
Statistical Analysis
ANOVA and Student t test were used to determine statistical significance. P values <0.05 were considered significant. Values for all measurements were expressed as the mean±SD.
Results
FOXF1 Is Expressed in Mesenchyme and Endothelial Cells During Embryogenesis
Immunostaining with FOXF1 antibodies was used to visualize FOXF1-expressing cells in E13.5 mouse embryos. FOXF1 protein was found in mesenchyme of the lung, trachea, esophagus, stomach, intestine, oral cavity, tongue, and cartilage ( Figure 1A-1I) , which is consistent with previous in situ hybridization studies. 11, 13 Additional site of FOXF1 expression was found in the embryonic heart where FOXF1 was present in mesenchyme of cardiac cushion but absent from myocardium and endocardial cells ( Figure 1E ; data not shown). FOXF1 was detected in hemangioblasts of the yolk sac but was absent from hematopoietic cells at E8.5 to E12.5 ( Figure 1O ; data not shown). FOXF1 was also detected in nuclei of endothelial cells of the lung, yolk sac, and embryonic regions of the placenta ( Figure 1J-1N ). FOXF1 protein colocalized with endothelial marker proteins Flk1, Isolectin B4, and Von Willebrand factor in lung tissue ( Figure 1P-1R) . Thus, FOXF1 is expressed in endothelial cells during embryogenesis. 
Embryonic Lethality and Cardiovascular Defects in
Tie2-Cre Foxf1 fl/fl Embryos
Tie2-Cre Foxf1 fl/fl embryos were present in Mendelian ratio before E13.5 (Table) . The number of Tie2-Cre Foxf1 fl/fl embryos progressively decreased from E13.5 to E16.5, consistent with embryonic lethality during this period (Table) . Histological examination of the Tie2-Cre Foxf1 fl/fl embryos revealed severe growth retardation as demonstrated by decreased embryo size and body weight ( Figure 3A ). Liver size was also decreased in FOXF1 mutants ( Figure 3B ). Deletion of FOXF1 caused ventricular hypoplasia and an interventricular septal defect in the embryonic heart (Online Figure IIA and IIB). Furthermore, FOXF1 mutants exhibited accumulation of fluid in the amniotic cavity (polyhydramnios) and pericardial cavity (pericardial efflux; Figure 3A ), a common finding in embryos with various cardiovascular abnormalities. 5, 6 Thus, deletion of FOXF1 resulted in embryonic lethality because of severe growth retardation and cardiovascular defects. and Foxf1 +/− embryos were less severe compared with Flk1-null mutant mice that exhibited growth retardation, a nearcomplete loss of yolk sac vasculature and embryonic lethality at E10.5 (Online Figure IIID) .
Vascular defects in Tie2-Cre Foxf1 fl/fl yolk sacs were associated with reduced Foxf1 mRNA ( Figure 4A ) and decreased expression of Flt1, Flk1, and angiopoietin-1 ( Figure 4B ), all of which are critical for angiogenesis and VEGF signaling in endothelial cells. 3, 4, 23, 31 Angpt2 and Nrp1 mRNAs were increased in FOXF1 mutants ( Figure 4B ). Expression of Ephrin B2 was reduced in arteries of Tie2-Cre Foxf1 fl/fl embryos (Online Figure IVA) as well as in isolated Pecam1 + endothelial cells fl/fl embryos. Occipital frontal diameter (OFD) of the liver and the ratio between OFD and the crown rump length (CRL) were significantly reduced after deletion of Forkhead Box transcription factor F1 (FOXF1; n=5). C and D, Diminished vascular branching in the yolk sac of FOXF1-deficient embryos. The whole-mount immunoistaining was performed using endomucin Abs. Confocal microscopy was used to quantify the vessel density as a ratio between endothelial (endomucin) and epithelial (E-cadherin) staining (bottom; D). *P<0.05, **P<0.01. Ht indicates, heart; Li, liver; and Lu, lung. Scale bars, 50 μm (A), 1 mm (B), 50 μm (C), and 100 μm (D). Figure IVB) . There were no differences in the number of lymphatic vessels stained for LYVE1 (Online Figure  IVA) . Ephrin b4, Sox-18, Foxc1, and Foxc2 mRNAs were unaltered (Online Figure IVB and IVC) . Interestingly, when the Tie2-Cre Foxf1 fl/fl embryos were examined at E10.5, diminished branching of blood vessels was still evident in the yolk sac and placenta ( Figure 3C ; data not shown), but cardiac abnormalities and polyhydramnios were absent ( Figure 3C ; Online Figure IIC) Figure VA) . Thus, vascular insufficiency in the yolk sac and placenta occurs earlier than other embryonic defects and is likely to be a primary cause of growth retardation and embryonic lethality in Tie2-Cre Foxf1 fl/fl embryos. Altogether, FOXF1 deletion from endothelial cells impairs heart development and decreases vascular branching in the yolk sac and placenta.
FOXF1 Deletion Impairs the Formation of Pulmonary Vascular Plexus
Because FOXF1 deficiency is associated with reduced numbers of pulmonary capillaries in ACD/MPV infants and 
Reduced Vascular Branching in Pdgfb-CreER Foxf1 fl/fl Embryos
Pdgfb-CreER Foxf1 fl/fl mouse line was generated to achieve an inducible deletion of Foxf1 from endothelial cells without targeting hematopoietic cells. To activate Cre, tamoxifen was given to pregnant females at E9.5, and embryos were harvested at E12.5. The Foxf1-null allele was detected in tamoxifentreated Pdgfb-CreER Foxf1 fl/fl mice by PCR ( Figure 5A ), a finding consistent with activation of Cre by tamoxifen. Cremediated recombination in lung tissue was confirmed by β-gal reporter and diminished FOXF1 immunostaining ( Figure 5B ). Flow cytometry showed that ≈60% of PECAM-1 + endothelial cells and only 2% of CD45 + hematopoietic cells in the yolk sac were positive for Cre ( Figure 5A ). Pdgfb-CreER Foxf1 fl/fl embryos exhibited polyhydramnios ( Figure 5A ), reduced vascular branching in the placenta and yolk sac ( Figure 5C ), and decreased numbers of endothelial cells in the lung ( Figure 5D ). Deletion of FOXF1 during the postnatal period (P0-P2) impaired retinal angiogenesis in Pdgfb-CreER Foxf1 fl/fl mice (Online Figure VI) . Thus, FOXF1 stimulates angiogenesis in the developing lung, eye, placenta, and yolk sac.
FOXF1 Stimulates Angiogenesis In Vitro
The ability of FOXF1 to stimulate angiogenesis in endothelial cells was directly tested in vitro. Small interfering RNA transfection was used to deplete FOXF1 mRNA and protein in endothelial MFLM-91U cells ( Figure 6B and 6C) . Depletion of FOXF1 reduced the ability of MFLM-91U cells to form vessel-like sprouts in matrigel ( Figure 6A ), a common model of angiogenesis in vitro. Diminished angiogenesis in FOXF1-depleted cells was associated with reduced proteins and mRNAs of Flk1, Flt1, Pecam-1, and Pdgfb, whereas Interestingly, VEGF-A ligand did not rescue the FOXF1-mediated decrease in angiogenesis ( Figure 6A and 6D) , a finding consistent with reduced expression of VEGF receptors in 
Decreased Proliferation and Increased Apoptosis in Endothelial Cells of Tie2-Cre Foxf1 fl/fl Embryos
VEGF induces cellular proliferation and inhibits apoptosis by activating the tyrosine kinase receptor Flk1, which is present on the surface of endothelial cells. 3, 6 Given that Flk1 mRNA and protein were decreased in FOXF1-deficient mice ( Figure 4B-4D ) and cultured MFLM-91U cells ( Figure 6B and 6C), we next determined whether FOXF1 affects endothelial proliferation and apoptosis in vivo. Yolk sacs from E12.5 embryos were enzymatically digested and cells were stained for the endothelial marker Pecam-1 and the hemato- 
FOXF1 Directly Regulates Expression of Endothelial Genes Critical for Angiogenesis and VEGF Signaling
To label endothelial cells that underwent Cre-mediated recombination, Tie2-Cre Foxf1 fl/+ mice were crossed with mT/ mG reporter mice that contain the LoxP-tdTomato-LoxP-GFP cassette knocked into the Rosa26 locus. The use of mTmG reporter enabled us to distinguish between Cre-targeted (GFP + ) and nontargeted (tdTomato Figure 7B ). We next used flow cytometry-based cell sorting to isolate GFP + and tdTomato + endothelial cells and use these cells for quantitative reverse transcriptase PCR. Loss of Foxf1 mRNA and decreased expression of the FOXF1 target gene, integrin β3, 20 were specifically found in GFP + endothelial cells compared with control tdTomato + endothelial cells ( Figure 7C ). Deletion of FOXF1 efficiently reduced mRNAs of Flk1, Flt1, Pdgfb, Pecam-1, CD34, Tie2, and the noncoding RNA Fendrr, all of which are critical for embryonic vascular development. [5] [6] [7] 32, 33 In contrast, Angpt2, Nrp1, Dll4, Notch2, and VEGFb mRNAs were increased ( Figure 7C ). There was no difference in expression levels of Notch1 and Notch target genes Hey2 and Hes1 ( Figure 7C) . Finally, ChIP assay demonstrated that FOXF1 protein directly bound to promoter DNAs of Flk1, Flt1, Pdgfb, Pecam-1, and Tie2 ( Figure 7D ), a finding consistent with a direct transcriptional regulation of these genes by FOXF1. FOXF1 protein did not bind to Nrp1 and Angpt2 promoters ( Figure 7D ). Thus, FOXF1 directly regulates expression of endothelial genes critical for angiogenesis and VEGF signaling.
Discussion
Although various vascular abnormalities were previously reported for Foxf1 −/− and Foxf1 +/− mouse embryos as well as for ACD/MPV infants with FOXF1 mutations, 9,13,14 cellular origins and molecular mechanisms of these developmental defects remain uncharacterized. In the present study, we showed that FOXF1 is expressed in endothelial cells and that endothelial deletion of FOXF1 causes a variety of developmental defects, including impaired vasculature in the yolk sac, placenta, lung, and retina. These data demonstrate that FOXF1 functions in a cell-autonomous manner to induce the formation of embryonic vasculature. This hypothesis is consistent with diminished angiogenesis in FOXF1-deficient endothelial MFLM-91U cells in vitro. Interestingly, during embryogenesis FOXF1 is abundantly expressed in endothelial cells of capillaries and small blood vessels of the yolk sac, placenta, and lung, but found only in a subset of endothelial cells of vena cava and pulmonary vein. In adult mice, FOXF1 was absent from endothelium of large pulmonary vessels but present in pulmonary capillaries. 34 Therefore, FOXF1 is not a marker of endothelial cells. It is possible that FOXF1 expression in endothelial cells depends on proliferation or differentiation status, or reflects endothelial responses to various stimuli.
Although Tie2-Cre Foxf1 fl/fl mutant mice exhibited a complex developmental phenotype, we think that vascular insufficiency in the yolk sac and placenta was a primary cause of growth retardation and embryonic lethality in Tie2-Cre Foxf1 fl/fl embryos. This conclusion is based on the fact that diminished branching of blood vessels was found at E10.5, whereas other developmental abnormalities such as cardiac defects and polyhydramnios occurred after E13.5. Vascular insufficiency in the yolk sac and placenta may alter embryonic circulation in FOXF1 mutants, causing secondary heart defects and polyhydramnios and contributing to embryonic death. Interestingly, FOXF1 is expressed in the cardiac cushion and important for mesenchyme migration 20 (and this article). Therefore, interventricular septal defect in Tie2-Cre Foxf1 fl/fl embryos can be a direct consequence of FOXF1 deletion from mesenchymal cells of cardiac cushion, which is critical for formation of interventricular septum and cardiac valves. FOXF1 was not detected in hematopoietic cells that are targeted by the Tie2-Cre transgene in our mouse model, and therefore, it is unlikely that FOXF1 deletion in hematopoietic cell lineages contributed to the vascular phenotype in FOXF1 mutant mice. However, we cannot exclude the possibility that FOXF1 is expressed in rare population(s) of hematopoietic progenitors, and targeting these cells contributed to the phenotype in Tie2-Cre Foxf1 fl/fl embryos. Interestingly, the Pdgfb-CreER transgene, which is more specific to endothelial cells compared with the Tie2-Cre, 22 caused similar defects in vascular development, suggesting that endothelial cells are the main cellular targets of FOXF1. It is also possible that FOXF1 deletion reduces the number of circulating endothelial progenitors or mesenchymal stem cells, contributing to September 26, 2014 vascular insufficiency in FOXF1-deficient embryos. Previous studies demonstrated that Foxc2 and Foxc1 genes are critical for vascular development in zebrafish and mice. 5, 32 We found no significant differences in expression of FOXC2 and FOXC1 after deletion of FOXF1. Because FOXC proteins and FOXF1 have high homology in their DNA-binding Published studies reported a direct correlation between FOXF1 levels and the number of pulmonary capillaries during lung development 14 and lung injury. 16 In the present study, we used in vivo and in vitro models to demonstrate that FOXF1 induces angiogenesis, endothelial proliferation, and VEGF signaling through transcriptional activation of VEGF receptors Flk1 and Flt1 (Figure 7) . Reduction of Flk1 and Flt1 in FOXF1 mutants is consistent with the role of these genes in stimulating proliferation and differentiation of endothelial cells, leading to formation and maturation of blood vessels. 3, 4 In addition to VEGF signaling, FOXF1 may influence other signaling pathways critical for endothelial development, such as PDGF and Angpt/Tie2 pathways. Reduced expression of Pdgfb and Tie2 may account for decreased proliferation and increased apoptosis of endothelial cells in FOXF1-deficient embryos. Our data also suggest that FOXF1 stimulates angiogenesis through transcriptional activation of integrin-β3, pecam-1, and lncRNA Fendrr, all of which are critical for vascular development. [5] [6] [7] 33 Altogether, disruption of several key endothelial cell regulators can contribute to the FOXF1 phenotype. Because FOXF1 is a downstream target of the Shh signaling pathway, 15, 18, 19 it is possible that FOXF1 mediates cross-talk between the Shh and VEGF pathways during development of embryonic vasculature. Our results suggest that inability of FOXF1-deficient endothelial cells to respond to VEGF, PDGF, and Angpt/Tie2 signaling is a key mechanism in development of alveolar capillary dysplasia in ACD/MPV fetuses and infants harboring inactivating mutations in the FOXF1 gene locus.
What Is Known?
• Inactivating mutations in the Forkhead Box transcription factor F1 (FOXF1) gene are found in 40% of patients with alveolar capillary dysplasia with misalignment of pulmonary veins.
• Haploinsufficiency of the Foxf1 gene causes alveolar capillary dysplasia and developmental defects in lung, intestinal, and gall bladder morphogenesis in mice.
• FOXF1 is a transcription factor, which is found in multiple cell types, including endothelial cells.
What New Information Does This Article Contribute?
• Disruption of Foxf1 gene in endothelial cells caused embryonic lethality, growth retardation, and cardiovascular abnormalities.
• Disruption of Foxf1 reduced cell proliferation, increased apoptosis, and inhibited the vascular endothelial growth factor (VEGF) signaling pathway in endothelial cells.
• FOXF1 induces transcription of VEGF receptor genes Flk1 and Flt1.
Inactivating mutations in the FOXF1 gene were recently found in 40% of human patients with alveolar capillary dysplasia with misalignment of pulmonary veins. The molecular mechanisms by which these mutations cause vascular defects remain unknown. In the present study, we used transgenic mice with endothelialspecific inactivation of the Foxf1 gene to demonstrate that FOXF1 is critical for formation of embryonic vasculature. FOXF1 stimulates endothelial proliferation and promotes the VEGF signaling pathway in embryonic endothelial cells through direct transcriptional activation of VEGF receptor genes. Our results suggest that inability of FOXF1-deficient endothelial cells to respond to VEGF signaling is a key mechanism in development of alveolar capillary dysplasia in alveolar capillary dysplasia with misalignment of pulmonary veins fetuses and infants harboring inactivating mutations in the FOXF1 gene. Pharmacological agents that stimulate or stabilize FOXF1 protein might serve as promising therapeutic agents in patients with alveolar capillary dysplasia with misalignment of pulmonary veins caused by heterozygous loss-of-function mutations in FOXF1 gene.
SUPPLEMENTAL MATERIAL
Detailed Methods
Mice. Tie2-Cre transgenic mice were purchased from Jackson Lab., whereas Pdgfb-CreER transgenic mice were obtained from Pierre Chambon RNA preparation and quantitative real-time RT-PCR (qRT-PCR). Total RNA was prepared from cultured MFLM-91U cells, mouse tissue and flow-sorted endothelial cells using RNeasy micro kit from Qiagen (Germantown, MD). qRT-PCR analysis was performed using a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA) as described 3 . Samples were amplified using inventoried TaqMan primers for the gene of interest as indicated in Online Table II . Reactions were analyzed in triplicates and expression levels were normalized to -actin mRNA. Five embryos were used in each group.
siRNA transfection, Western blot and matrigel angiogenesis assay. MFLM-91U cells were cultured in serum-free UltraCULTURE medium (Lonza, Walkersville, MD). To inhibit FOXF1, we transfected siRNA specific to mouse Foxf1 (siFoxf1, 5 -GAA AGG AGU UUG UCU UCU C-3', Dharmacon) using Lipofectamine TM 2000 reagent (Invitrogen) as described 4, 5 . Controls included mocktransfected cells and cells transfected with control non-targeting siRNA (Dharmacon). Cells were harvested 48 hours after transfection and used for matrigel angiogenesis assay (BD Biosciences). VEGF 165 (20 ng/ml, Millipore) was added to matrigel for 14 hr. Cells in matrigel were stained with calcein AM fluorescent viability dye which is transported through the cellular membrane into live cells. 3D images were acquired using a Nikon Eclipse Ti confocal microscope in conjunction with NISElements AR software. Vessel filament total length and circularity were measured using IMARIS software (Bitplane, CT).
Western Blot analysis was performed using following antibodies: Foxf1
4
, Pecam-1 (ABCAM, Cat# ab28364-100), Flk1 (Santa Cruz, Cat# SC-6251), Flt1 (R&D, Cat# AF471), Pdgfb, (Aviva Systems Biology, Cat# ARP58509), Angpt2 (Rockland, Cat# 100-401-402), p-ERK 1/2 (Cell signaling, clone D13.14.4E), total ERK 1/2 (Cell signaling, clone 137F5), p-Akt (Cell signaling, clone 736E11), total Akt (Cell signaling, clone 11E7) and -actin (Sigma, clone AC-15). Detection of the immune complex was accomplished by using secondary antibodies directly conjugated with HRP followed by the Supersignal chemiluminescence substrate (Pierce, Rockford, IL).
Immunohistochemical staining and Flow cytometry. Paraffin sections were stained with hematoxylin and eosin (H&E) or used for immunohistochemical staining as described 6, 7 . The following antibodies were used for immunohistochemistry: FOXF1 4 , Pecam-1 (ABCAM, Cat# ab28364-100), Sox-17 (generated in Dr. Whitsett lab), Flk1 (Cell signaling, Cat# 55B11), LYVE-1 (Novas biologicals, Cat# NB100-725), Ephrin B2 (R&D systems, Cat# AF496) and endomucin (R&D systems, Cat#AF4666). Antibody-antigen complexes were detected using biotinylated secondary antibody followed by avidinhorseradish peroxidase (HRP) complex and DAB substrate (Vector Labs, Burlingame, CA). Sections were counterstained with nuclear fast red. To stain endothelial cells, Alexa Fluor 488-conjugated Isolectin B4 (Invitrogen) was used according to manufacturer recommendations and previous studies 8 . For co-localization experiments, secondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen) were used. Slides were counterstained with DAPI (Vector Lab). Fluorescent images were obtained using a Zeiss Axioplan2 microscope equipped with an AxioCam MRm digital camera and AxioVision 4.3 Software (Carl Zeiss Microimaging, Thornwood, NY).
Flow cytometry was performed using cells isolated from yolk sacs and lungs as described 7, 9 . Cells were stained with fluorescently-labeled antibodies against CD45 (eBioscience, clone 30-F11), CD41 (eBioscience, clone eBioMWReg30), Tie2 (eBioscience, clone TEK4), endomucin (eBioscience, clone eBioV.7C7), Pecam-1 (eBioscience, clone 390) or BrdU (eBioscience, clone BU20A). BrdUlabeling reagent (Invitrogen) was injected i.p. into pregnant females 2 hr prior to embryo harvest. Apoptosis was measured using the Annexin V kit (eBioscience). Cells stained with fixed viability dye, CD45 and Pecam-1 Abs were separated using cell sorting (Five-laser FACSAria II, BD Biosciences). Purified cells were used for RNA preparation and qRT-PCR analysis.
Chromatin Immunoprecipitation (ChIP) assay. ChIP assay was performed with in situ crosslinked MFLM-91U cells as described 3, 7 . Nuclear extracts from MFLM-91U cells were cross-linked by addition of formaldehyde, sonicated and used for the immunoprecipitation with Abs against FOXF1 4 or control rabbit IgG (Vector Lab). DNA fragments were 500-700 bp. Reverse cross-linked ChIP DNA samples were subjected to PCR using the oligonucleotides specific to promoter regions of potential FOXF1-target genes. Sense (S) and antisense (AS) PCR primers that were used to amplify mouse promoter DNA fragments in ChIP assay are provided in Online Table III .
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